180 related articles for article (PubMed ID: 1770154)
1. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
3. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
Elizur A; Segal Z; Yeret A; Ben-David M
Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
[No Abstract] [Full Text] [Related]
4. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T; Marder SR; Mintz J; Poland RE
Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
8. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
9. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
[TBL] [Abstract][Full Text] [Related]
11. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
[No Abstract] [Full Text] [Related]
12. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
[TBL] [Abstract][Full Text] [Related]
15. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
17. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
18. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
19. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
20. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
